Arno Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARNI research report →
Companywww.arnothera.com
Arno Therapeutics, Inc. , a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men.
- CEO
- David M. Tanen
- IPO
- 2008
- Employees
- 4
- HQ
- Flemington, NJ, US
Price Chart
Valuation
- Market Cap
- $9.87K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 250.44%
- ROIC
- 755.35%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-11,536,366 · -248.46%
- EPS
- $-0.57 · -250.00%
- Op Income
- $-13,411,811
- FCF YoY
- 47.06%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.55
- Avg Volume
- 461.04
Get TickerSpark's AI analysis on ARNI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 25, 13 | Kariv Tomer | other | 0 |
| Jan 25, 13 | Kariv Tomer | other | 0 |
| Jan 25, 13 | Kariv Tomer | other | 0 |
| Aug 15, 16 | Belldegrun Arie | buy | 714,285 |
| Aug 15, 16 | Belldegrun Arie | buy | 357,142 |
| Aug 15, 16 | Kariv Tomer | buy | 349,168 |
| Aug 15, 16 | Kariv Tomer | buy | 263,017 |
| Aug 15, 16 | Kariv Tomer | buy | 102,100 |
| Aug 15, 16 | Kariv Tomer | buy | 174,584 |
| Aug 15, 16 | Kariv Tomer | buy | 131,508 |
Our ARNI Coverage
We haven't published any research on ARNI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARNI Report →